EUDA Health Holdings Limited (EUDA) AI Stock Analysis

EUDA Health Holdings Limited is a healthcare specialty company headquartered in Singapore. The company offers a wide range of specialty care services, including operating a general practice clinic within a medical facility to deliver comprehensive care for diverse medical needs and illnesses. In addition to healthcare services, EUDA is involved in property management. The company oversees various real estate assets, including shopping malls, business office buildings, and residential apartments, aiming to improve community environments and service offerings. EUDA integrates these two primary operations to serve the multifaceted requirements of its clients and communities across Singapore.

EUDA generated $6.8M in revenue during FY2025, representing 70.0% growth over FY2024 revenue of $4.0M. Gross margin improved to 43.9% in FY2025 from 19.0% in FY2024, while operating margin narrowed to -35.8% compared to -432.2% in FY2024. Net loss was -$2.8M in FY2025, an improvement from -$15.4M in FY2024. Over a 5-year period from FY2020 to FY2025, revenue posted a CAGR of -5.1%. For the trailing twelve months ended June 30, 2026, revenue stood at $7.2M with quarterly revenue growth of 13.4% year-over-year, an operating margin of -22.0%, and an EPS of -$1.05.

As of June 30, 2026, EUDA held $365,904 in cash and short-term investments alongside $339,985 in total debt, resulting in net cash of $25,919. Total assets were $9.7M against shareholders' equity of $6.0M. The company had a current ratio of 2.53 and a debt-to-equity ratio of 0.06. In FY2025, free cash flow was negative at -$2.5M, operating cash flow was -$2.4M, and capital expenditures were $104,450. Over five years, the company's share count increased by 355.2%.

At $15.40 per share, EUDA has a market capitalization of $46.1M and an enterprise value of $53.9M. EUDA trades at a forward P/E of 7.8x, compared to the 23.5x median of its US-listed Real Estate peers. Its price-to-sales multiple is 6.4x, above the peer median of 3.7x, while its EV-to-revenue ratio is 7.9x. Over the past 12 months, EUDA stock fell 77.5%, lagging the S&P 500 return of 16.8%.

Wall Street coverage includes 1 Strong Buy rating, with no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $55.00, representing 257.1% above the last close of $15.40. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $27.2M and EPS of $1.60, indicating expected EPS growth of 208.1%. EUDA has beaten EPS estimates in 1 of the last 4 quarters.

This page is an AI-written research summary of EUDA Health Holdings Limited (EUDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EUDA income statement, EUDA balance sheet, EUDA key metrics, EUDA analyst forecast, EUDA chart. See the EUDA stock overview for the latest quote and news.